Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma

Inclusion Criteria: * Written informed consent. * Age \> or = to 18 years. * Histologically confirmed diagnosis of conventional chondrosarcoma of any grade. * Surgically unresectable or metastatic disease. * Any number of prior treatment regimens, including treatment naive subjects. Prior treatment with tyrosine kinase inhibitors is permitted. * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. * Measurable or evaluable (non-measurable) disease per RECIST guidelines version 1.1. * Adequate organ system function determined within 14 days prior to first dose of study treatment. * Left ventricular ejection fraction \> 50% or the institutional LLN within 28 days prior to the first dose of study treatment. * Females must either be of non-child bearing potential or have a negative serum pregnancy test within 7 days prior to the first dose of study treatment. Exclusion Criteria: * Prior treatment with pazopanib. * Mesenchymal, dedifferentiated, and extraskeletal myxoid chondrosarcoma subtypes. * Prior malignancy (Note: subjects who have had another malignancy and have been disease-free for 3 years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible). * History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, unless previously treated, asymptomatic, and off steroids and anti-seizure medication for 6 months prior to first d…